The RELAY trial is an ongoing phase Ib/III trial that assesses the efficacy and safety of first-line ramucirumab in combination with erlotinib in patients with advanced NSCLC who harbor a sensitive EGFR mutation (NCT02411448) [83]. Here, EGFR is linked to non-small cell lung carcinoma.